Who is sponsoring NCT03851328?

NCT03851328 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT03851328?

Interventions in NCT03851328: BPMH structured interview.

What condition does NCT03851328 study?

NCT03851328 studies Best Possible Medication History.

Is NCT03851328 still recruiting?

NCT03851328 is currently completed. Last updated 6 May 2020.

Last reviewed 2020-05-06 · How we verify

NCT03851328: bpmh@USB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Best Possible Medication History at USB

Completed Last updated 6 May 2020

What this trial tests

trial testing BPMH structured interview in Best Possible Medication History in 160 participants. Completed in 30 December 2019.

Timeline

1 September 2017

Primary endpoint
31 October 2017

30 December 2019

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Status	Completed
Study type	OBSERVATIONAL
Enrollment	160
Start date	1 September 2017
Primary completion	31 October 2017
Estimated completion	30 December 2019
Sites	1 location across Switzerland

Drugs / interventions tested

BPMH structured interview

Conditions studied

Best Possible Medication History — all drugs for Best Possible Medication History →

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Best Possible Medication History. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot project investigates the use of a structured medication history (Best Possible Medication History, BPMH) in patients (primarily admitted at the emergency department of University Hospital Basel) after transfer to a medical ward. Unintentional medication discrepancies are analyzed comparing outpatient and inpatient medication therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03851328 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 6 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03851328.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing